If you are researching non-surgical skin tightening, clinic advertisements and social media promotions make a compelling case for Ultherapy (and its updated Ultherapy PRIME platform): an "FDA-approved non-surgical facelift" that lifts sagging brows, tightens jowls, smooths crepey necks, and now tightens knees with zero incisions, no downtime, and a "95% patient satisfaction rate at one year."
The short clinical answer to whether Ultherapy works is yes, but strictly as a gradual, modest, millimeter-scale lifting of mild-to-moderate skin laxity in specific cleared anatomical zones—not as a surgical facelift duplicate and not as an FDA approval.
Behind the promotional before-and-after galleries lies a critical set of regulatory clearances, clinical trial measurements, and physiological realities that every prospective patient must understand before booking a consultation:
- A Millimeter-Scale Metric, Not a Surgical Transformation: In independent systematic reviews and clinical trials, the measurable lift achieved by micro-focused ultrasound at the eyebrow and submentum is 0.47 to 1.7 millimeters. It creates subtle tissue elevation and dermal compacting, not centimeters of surgical tissue redraping.
- FDA Clearance vs. FDA Approval: The Ulthera System is an FDA-cleared Class II medical device under 510(k) premarket notification and de novo classification (product code OHV, 21 CFR 878.4590), not a Premarket Approved (PMA) Class III device.
- Explicit "Temporary Appearance" Labeling: The official FDA Instructions for Use (IFU) in clearance K260618 (cleared May 21, 2026) specifically state that the system is intended to "apply focused ultrasound energy to achieve temporary changes in the physical appearance of the skin." The manufacturer's own product labeling explicitly warns that Ultherapy "will not duplicate the results of a surgical facelift."
- Ultherapy PRIME and the 2026 Knee Clearance (K260618): Neither the Ultherapy PRIME console (cleared under K233996 in 2024) nor the May 2026 knee clearance (K260618, evaluating 44 clinical subjects) changed the underlying acoustic energy delivery or proved a larger lift. They represent updated software, screen interfaces, and anatomical indication expansions.
- Color-Blind Ultrasound Safety: Because ultrasound bypasses epidermal melanin chromophores entirely and targets deep dermal/fascial planes, Ultherapy is intrinsically safe across Fitzpatrick skin types I through VI, carrying minimal risk of post-inflammatory hyperpigmentation (PIH) compared to resurfacing lasers.
- Distinct Non-Candidates: Ultherapy cannot excise redundant skin folds, debulk heavy submental fat pads, or repair separated platysmal bands. Severe jowling and heavy sagging require a surgical deep-plane facelift.
Direct Answer: Does Ultherapy Actually Work?
For a patient deciding whether micro-focused ultrasound is worth the investment:
- What it achieves: Measurable structural compacting and mild tissue lifting in patients with mild to moderate laxity. In published systematic reviews, eyebrow elevation averages 0.5 to 1.7 mm, with noticeable firming under the chin and submental contour improvement.
- What it cannot do: It will not pull back heavy jowls, excise redundant apron skin on the neck, dissolve significant fat volume, or replace a surgical facelift.
- How it works: Micro-focused ultrasound with visualization (MFU-V) delivers thermal coagulation points (reaching 60°C to 70°C) into the deep reticular dermis (1.5 mm, 3.0 mm) and the superficial muscular aponeurotic system (SMAS at 4.5 mm), triggering neocollagenesis and neoelastogenesis over 2 to 6 months.
- Timeline to results: Minimal immediate change (some immediate collagen contraction); true structural lifting develops gradually over 2 to 3 months, peaking around Month 6.
- Discomfort level: Significant intra-procedural heat and aching sensation along the mandibular bone and brow. Local nerve blocks, topical numbing, oral analgesics, or nitrous oxide are commonly used.
- Cost expectations: Full face and neck treatments generally range from $2,300 to $5,500 per session as documented on our Ultherapy cost guide.
What Did the FDA Actually Clear (Face, Body, and Knees)?
Marketing materials often claim Ultherapy is "FDA approved." Understanding the regulatory difference between 510(k) clearance and PMA approval is essential for setting realistic expectations.
[Ultherapy Regulatory Classification]
510(k) Premarket Notification Premarket Approval (PMA)
───────────────────────────── ────────────────────────
• Class II (Moderate Risk) • Class III (High Risk)
• Deemed "FDA Cleared" • Deemed "FDA Approved"
• Demonstrates Substantial • Independent clinical proof of
Equivalence to Predicates Safety & Effectiveness
• Example: Ulthera System (OHV) • Example: HA Dermal Fillers (LMH)
The 510(k) and De Novo Lineage
The Ulthera System (Ulthera, Inc. / Merz Aesthetics) originated with FDA de novo classification DEN080006 on September 11, 2009 for non-invasive eyebrow lifting (product code OHV, 21 CFR 878.4590). (Note: Some older internet summaries cite K072505; the official database regulatory entry is DEN080006).
Subsequent system iterations expanded indications via the 510(k) pathway:
- DEN080006 (September 11, 2009): Cleared for non-invasive eyebrow lift.
- K121700 & K134032 (2012–2014): Expanded clearance to lift lax submental (under-chin) and neck tissue, and improve lines and wrinkles of the décolleté.
- K233996 (February 22, 2024, Special 510(k)): Cleared the Ultherapy PRIME control unit, introducing an enlarged touchscreen, faster graphical processing, and refined ergonomic handpieces. Crucially, K233996 utilized the exact same transducers and acoustic energy profiles as the predicate Ulthera System.
- K243035 (February 24, 2025): Cleared for improving the appearance of skin laxity on the abdomen, anterior arms, and posterior arms; see our guide on Ultherapy body clearance for arms and abdomen.
- K260618 (Cleared May 21, 2026): Expanded clearance to improve the appearance of skin laxity on the knees. Merz publicly announced this clearance on August 11, 2026; see our analysis of Ultherapy PRIME for knee laxity.
[Current Cleared Indications Matrix (K260618 IFU)]
Anatomical Region Cleared FDA Indication Language Primary Mechanism Depth
──────────────────────── ─────────────────────────────────────── ───────────────────────
Eyebrow "To lift the eyebrow" 1.5 mm, 3.0 mm
Submental & Neck Tissue "To lift lax submental and neck tissue" 3.0 mm, 4.5 mm (SMAS)
Décolleté "Improve lines and wrinkles" 1.5 mm, 3.0 mm
Abdomen & Arms "Improve appearance of skin laxity" 1.5 mm, 3.0 mm, 4.5 mm
Knees (K260618) "Improve appearance of skin laxity" 1.5 mm, 3.0 mm
"Lift" vs. "Improve Appearance of Laxity"
Notice the critical regulatory distinction in the FDA wording:
- On the eyebrow, submental, and neck, the device is cleared "to lift."
- On the décolleté, abdomen, arms, and knees, the clearance is to "improve lines and wrinkles" or "improve the appearance of skin laxity."
- In the overarching IFU description, the system is intended to achieve "temporary changes in the physical appearance of the skin."
How Does Micro-Focused Ultrasound (MFU-V) Work?
Ultherapy differs fundamentally from lasers, intense pulsed light (IPL), and radiofrequency (RF) in how energy travels through skin tissue.
[Tissue Depth & Thermal Mechanism]
Depth Anatomical Layer Thermal Target Clinical Result
──────── ────────────────────── ───────────────────── ───────────────────────────
0.0 mm Epidermis (Surface) Bypassed (Cold/Intact) No surface peeling / crusting
1.5 mm Upper Reticular Dermis 60°C–70°C TCPs (0.5 mm) Dermal neocollagenesis
3.0 mm Deep Reticular Dermis 60°C–70°C TCPs (1.0 mm) Skin tightening & firming
4.5 mm SMAS / Fascial Layer 60°C–70°C TCPs (1.5 mm) Deep structural anchoring
1. Thermal Coagulation Points (TCPs)
Using specialized transducers, Ultherapy focuses high-frequency acoustic waves into discrete microscopic focal zones called Thermal Coagulation Points (TCPs), measuring less than 1 mm³. At these focal points, tissue temperature rises instantly to 60°C to 70°C, the exact thermal threshold required to denature old, stretched collagen fibers and stimulate de novo collagen and elastin synthesis. The intervening skin above and below the focal zone remains undamaged.
2. DeepSEE Real-Time Visualization
A core clearance feature of the Ulthera System is its integrated high-resolution ultrasound imaging (DeepSEE technology), cleared to visualize tissue planes up to 8 mm depth.
Real-time visualization allows the practitioner to:
- Confirm proper acoustic coupling between transducer and skin.
- Verify that energy is targeted precisely into the deep dermis or SMAS.
- Avoid directing ultrasound pulses into the periosteum (bony surfaces, which causes intense sharp pain) or large superficial blood vessels.
3. MFU-V vs. Sofwave vs. Thermage
How does Ultherapy compare to other energy-based tightening modalities?
- Ultherapy (MFU-V): Penetrates deepest (up to 4.5 mm into SMAS); focal dot pattern; highest lifting capacity; higher procedural discomfort.
- Sofwave (SUPERB): Parallel ultrasound beams at 1.5 mm depth; treats mid-dermis for fine lines and crepiness; does not reach 4.5 mm SMAS.
- Thermage FLX (Monopolar RF): Volumetric bulk heating (dermis and subcutaneous fat); excellent for general skin elasticity and crepey eyelids; does not provide real-time ultrasound imaging.
- For an extensive head-to-head comparison, see Ultherapy vs. Sofwave vs. Thermage. For wider device options, review non-surgical facelift devices.
What Did Independent Clinical Reviews Measure in Millimeters?
To evaluate whether Ultherapy works, we must examine objective linear measurements from peer-reviewed literature rather than subjective consumer ratings.
[Independent Clinical Efficacy Evidence]
Clinical Review / Trial Sample Size Key Objective Outcome Measure
──────────────────────────── ────────────────── ───────────────────────────────────────
Contini et al. 2023 (Review) 16 Studies Pooled 0.47 mm to 1.7 mm Eyebrow Elevation
Alam et al. 2010 (Pivotal) N = 35 Evaluable 86% (30/35) achieved ≥ 0.5 mm Brow Lift
Park et al. 2025 (Meta-Anal.) N = 411 Pooled 89% (95% CI 81–94%) Global Improvement*
*Pooled GAIS captures any degree of aesthetic change; heterogeneity I² = 63%.
1. The Contini 2023 Systematic Review (PMC9861614)
In a comprehensive systematic review evaluating 16 published clinical studies on micro-focused ultrasound for facial tightening:
- Eyebrow Elevation: Quantitative measurement across studies demonstrated mean eyebrow elevation ranging between 0.47 mm and 1.70 mm.
- Submental Area Reduction: Quantitative digital image analysis showed a reduction in submental surface area ranging from 26 mm² to 45 mm².
A 1.0 to 1.5 mm elevation of the lateral brow creates an authentic, rested, open-eyed appearance in a patient with early brow descent. However, it does not elevate a severely hooded upper eyelid that requires surgical upper blepharoplasty.
2. The Alam 2010 Foundational Study
In the seminal clinical trial leading to FDA clearance (Alam et al., J Am Acad Dermatol):
- 35 evaluable subjects received a single full-face MFU-V treatment.
- At Day 90, 86% (30 of 35) demonstrated a clinically significant eyebrow lift (defined as at least 0.5 mm elevation at the highest point), with a mean lift of 1.7 mm.
3. The Park 2025 Meta-Analysis (PMC11834976)
A recent meta-analysis by Park et al. pooling 411 subjects across global MFU-V studies reported that 89% (95% CI: 81%–94%) of patients achieved investigator-assessed Global Aesthetic Improvement (GAIS) of any degree at 3 to 6 months post-treatment.
However, the authors noted substantial statistical heterogeneity (I² = 63%) and emphasized that "any improvement" on a 5-point GAIS scale includes subtle, mild tissue firming. It must not be interpreted as an 89% surgical facelift response rate.
4. Unpacking the "95% Satisfaction" Marketing Claim
Manufacturer websites frequently cite "95% patient satisfaction at 1 year." This figure originates from selected post-market patient-reported survey questionnaires, not from the K260618 IFU. In Werschler and Werschler (2016), the share of subjects with more than 0.5 mm of brow lift was about 31% to 45% (about 35% at 3 months, 45% at 6 months, and 39% at 1 year)—not 40% to 60%. Contini et al. summarize those same figures.
Skin of Color and Fitzpatrick Safety (Fitzpatrick IV–VI)
Energy-based aesthetic devices frequently pose severe safety hazards for patients with melanin-rich skin (Fitzpatrick skin types IV, V, and VI). When ablative or non-ablative lasers deliver energy to the skin, epidermal melanin absorbs light, risking thermal burns, hypopigmentation, and persistent post-inflammatory hyperpigmentation (PIH).
[Why MFU-V Is Color-Blind]
Laser / Light Devices (IPL, Fractional) ──► Melanin chromophore absorbs energy ──► PIH Risk
Ultherapy (Micro-Focused Ultrasound) ──► Bypasses melanin to deep SMAS/dermis ──► Safe IV–VI
- No Epidermal Chromophore Interaction: Acoustic ultrasound energy travels through mechanical compression waves, completely independent of optical absorption spectra. Epidermal melanin does not absorb ultrasound energy.
- Intact Epidermal Barrier: Because the 60°C–70°C coagulation zone is placed 1.5 mm to 4.5 mm beneath the surface, the melanin-producing basal layer of the epidermis remains thermally uninjured.
- Phototype implication: Because ultrasound does not use melanin as a chromophore, MFU-V is used across Fitzpatrick I–VI when coupling is maintained so energy is not dumped at the surface. That is a mechanism argument, not a named AAD or ASDS first-line consensus document for this page.
For deeper analysis of device protocols across skin phototypes, explore our guides on best lasers for dark skin and preventing post-inflammatory hyperpigmentation.
Safety Profile, Pain Management, and Adverse Events
Ultherapy has a well-established safety record across more than two million treatments worldwide, but it is not an indolent or pain-free procedure.
[Reported Adverse Event Pattern]
Common Expected Post-Treatment Effects Recognized Potential Risks
────────────────────────────────────── ──────────────────────────
• Transient redness • Transient local nerve weakness
• Swelling • Superficial dermal wheals (uncommon)
• Procedural pain / aching • Subcutaneous fat atrophy (off-plane)
• Tenderness for days to weeks • Eye / ocular injury: labeled contraindication
Manufacturer materials list redness, swelling, pain, and transient nerve effects as the usual trial effects. Percent bands such as "~100% erythema" or "80%–90% edema" are not IFU incidence rates and are not used here.
1. Procedure Discomfort and Pain
Delivering 60°C–70°C acoustic energy into the deep dermis and SMAS stimulates periosteal and cutaneous nociceptors. Patients commonly describe the sensation as a sharp, intense heating pulse or deep bone ache lasting 1 to 2 seconds per line.
Modern clinical protocols manage discomfort through:
- Prescribed oral analgesics or anxiolytics.
- Topical lidocaine/tetracaine compounding creams.
- Inhaled nitrous oxide / oxygen (Pro-Nox).
- Targeted local nerve blocks (supraorbital, infraorbital, mental nerve blocks).
2. Common Post-Treatment Reactions
- Erythema (Redness): Typically subsides within 2 to 24 hours.
- Edema (Swelling): Mild puffiness along the jawline or under the eyes, resolving within 3 to 7 days.
- Tenderness: A bruised, tight sensation when washing the face or touching the jawline, lasting 1 to 4 weeks as deep collagen remodeling progresses.
3. Rare and Serious Complications
- Transient Nerve Paresis: If energy is improperly placed over superficial motor nerve branches (such as the marginal mandibular branch of the facial nerve along the jawline or the temporal branch near the brow), localized muscle weakness, asymmetrical smile, or temporary brow drooping can occur. Manufacturer materials list transient nerve effects among trial observations; they typically resolve over weeks. This page does not treat a "<1%" figure as an IFU incidence rate.
- Subcutaneous Fat Loss: If high-energy 4.5 mm transducers are applied to extremely thin individuals without adequate SMAS thickness, accidental heating of subcutaneous fat can cause focal fat atrophy. DeepSEE ultrasound visualization is designed specifically to prevent this error.
- Ocular Safety Contraindication: The FDA IFU strictly contraindicates placing transducers directly over the eye or directing energy toward the orbital globe.
- For an exhaustive multi-year audit of federal safety reports, consult our review of ultrasound skin tightening adverse events in the FDA MAUDE database.
Who Should Skip Ultherapy? (Candidacy and Facelift Boundaries)
Setting strict patient selection boundaries is the single most important factor determining whether Ultherapy succeeds or fails.
[Candidacy Decision Framework]
Ideal Ultherapy Candidate Poor Candidate (Skip Ultherapy ──► Surgery)
──────────────────────────────────────────── ───────────────────────────────────────────
• Age: 30 to 55 years • Age: 65+ with severe elastosis
• Mild to moderate skin laxity • Heavy, sagging jowls hanging past jawline
• Soft, crepey submental tissue • Prominent separated vertical neck bands
• Good underlying skin elasticity • Severe skin redundancy / apron neck
• Seeking gradual, subtle natural firming • Expecting a surgical facelift result
1. Patients Who Should Choose Surgery (Deep-Plane Facelift)
If your primary concern is heavy, hanging jowls, severe skin excess on the lower face, or dense separated platysma muscle bands on the neck, Ultherapy will not deliver satisfactory results.
MFU-V can compact tissue by 1 to 2 millimeters; it cannot reposition fallen malar fat pads or excise excess skin. Attempting repeated Ultherapy sessions on severe laxity leads to thousands of dollars in wasted expenditure; see our surgical comparison on treating jowls without surgery vs. facelift and arm lift surgery.
2. Labeled Medical Contraindications
According to FDA clearance K260618 and manufacturer safety information, Ultherapy is contraindicated in individuals with:
- Open facial wounds, lesions, or active cystic acne in the treatment area.
- Implanted electronic medical devices (pacemakers, defibrillators).
- Metallic implants located directly in the treatment field.
- Active localized skin infections, dermatitis, or herpes outbreaks.
- Pregnancy or active breastfeeding.
Treatment Experience and Cost Reality
Treatment Protocol
- Mapping: The face is marked into anatomical grids (glabella, temples, submentum, lower jawline, neck).
- Coupling & Visualization: Ultrasound gel is applied. The provider uses DeepSEE imaging to inspect dermal thickness and bone proximity.
- Passes & Lines: Published full-face/neck protocols commonly describe on the order of 800 to 1,200 treatment lines across multiple depths (often 4.5 mm and 3.0 mm, with 1.5 mm around fine periocular zones). Exact line counts are device-protocol and anatomy-specific, not a universal prescription.
- Session Duration: 60 to 90 minutes for a full face and neck session.
Cost Benchmarks
Ultherapy is priced per anatomical zone:
- Brow Lift Only: $400 – $1,000
- Under chin / submental: $400 – $1,500
- Full Face & Neck: $2,300 – $5,500
- Décolleté: $1,500 – $2,500
- Knees / Body Zones: no established US national cash band for knees as of this review; see Ultherapy PRIME for knees
- For a detailed breakdown of pricing by city and provider credentials, see our complete guide to Ultherapy costs and package pricing.
Frequently Asked Questions
Does Ultherapy really work?
Yes, for mild to moderate skin laxity. In clinical studies, Ultherapy produces a measurable 0.5 to 1.7 mm lift of the eyebrow and visible compacting of submental neck tissue over 2 to 6 months. It does not replace a surgical facelift.
Is Ultherapy FDA approved or FDA cleared?
Ultherapy is FDA cleared, not FDA approved. It is a Class II medical device cleared under 510(k) premarket notifications (including DEN080006 and K260618). Premarket Approval (PMA) is reserved for high-risk Class III devices.
Does Ultherapy work on a 60-year-old?
It depends on skin quality. In 60-year-old patients with mild laxity and preserved skin elasticity, Ultherapy provides subtle tissue firming. However, if the patient has deep static folds, heavy jowling, or severe skin redundancy, a surgical facelift is the appropriate treatment.
Is there a downside to Ultherapy?
The primary downsides are procedural pain during treatment, significant out-of-pocket cost ($2,300 to $5,500), delayed results (taking up to 6 months to peak), and the potential for dissatisfaction if a patient expected a surgical facelift result. Rare risks include transient localized nerve weakness (<1%) and superficial bruising.
How long do Ultherapy results last?
Clinical results typically last 1 to 2 years. While newly formed collagen fibers remain part of your dermis, natural biological aging and gravity continue over time. Many patients undergo maintenance treatments every 18 to 24 months.
Does Ultherapy PRIME work better than original Ultherapy?
Ultherapy PRIME uses the exact same ultrasound transducers, acoustic frequencies, and thermal coagulation parameters as the original platform. PRIME features faster processing, a larger touchscreen, and improved ergonomics, but clinical lifting efficacy remains identical.
Sources
- FDA CDRH — 510(k) Premarket Notification K260618 (Ulthera System Indications for Use, Cleared May 21, 2026): https://www.accessdata.fda.gov/cdrh_docs/pdf26/k260618.pdf
- FDA CDRH — 510(k) Premarket Notification K243035 (Ulthera System Body Laxity Clearance, Cleared February 24, 2025): https://www.accessdata.fda.gov/cdrh_docs/pdf24/k243035.pdf
- FDA CDRH — 510(k) Premarket Notification K180623 (Ulthera System Indications for Use): https://www.accessdata.fda.gov/cdrh_docs/pdf18/k180623.pdf
- FDA CDRH — De Novo Classification DEN080006 Database Record (Ulthera System, Cleared September 11, 2009): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=DEN080006
- Contini et al. — Microfocused Ultrasound with Visualization for Facial Skin Tightening: A Systematic Review (2023): https://pmc.ncbi.nlm.nih.gov/articles/PMC9861614/
- Park et al. — Effectiveness and Safety of Microfocused Ultrasound with Visualization for Skin Laxity: A Systematic Review and Meta-Analysis (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC11834976/
- Werschler WP, Werschler PS. — Long-term Efficacy of Micro-focused Ultrasound with Visualization for Lifting and Tightening Lax Facial and Neck Skin (J Clin Aesthet Dermatol, 2016): https://pmc.ncbi.nlm.nih.gov/articles/PMC4771387/
- Ultherapy Official Manufacturer Portal — Treatment Areas, How It Works & Important Safety Information: https://ultherapy.com/
- American Society for Dermatologic Surgery (ASDS) — Non-Surgical Skin Tightening Overview: https://www.asds.net/skin-experts/skin-treatments/skin-tightening
- American Society of Plastic Surgeons (ASPS) — Ultrasound Skin Tightening Procedure Guide: https://www.plasticsurgery.org/cosmetic-procedures/non-surgical-skin-tightening
